Signum Biosciences, Inc. Names Braham Shroot as Chief Executive Officer

Signum Biosciences, Inc. Names Braham Shroot as Chief Executive Officer
PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer. Dr. Shroot replaces Dr. Gregory Stock who will continue to remain active with the Company as a member of the board.

"Braham Shroot brings to Signum an outstanding track record of success in growing value at both start-up and major pharmaceutical companies including Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock, President of Signum Biosciences. "We welcome him to the Signum team and look forward to seeing the company progress under his leadership."

"This is a very exciting time for Signum, with the commercialization of the company's first skin-care compound, ArazineTM, by its partner, Rohto Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about Signum's innovative pipeline which holds significant potential to help patients with difficult-to-treat chronic inflammatory and age related pathologies."

Braham Shroot Biography

Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public dermatology-focused pharmaceutical company, which was acquired by Stiefel Laboratories Inc., in August 2008. Prior to Barrier, Dr. Shroot was CSO and Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated private specialty pharmaceutical company with a focus on skin, wound care, and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was Group Leader and eventually Vice General Manager of the newly created Galderma entity which he helped to establish. Dr. Shroot earned his B.Sc. in Chemistry and Ph.D. in Organic Chemistry at Glasgow University, Scotland, UK. He is also a board member of the Wound Healing Society, and associate Editor of the Journal of Investigative Dermatology.

About Signum Biosciences

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for inflammatory and neurodegenerative diseases. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website: www.signumbiosciences.com

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.